| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
700,840,000 |
| Market
Cap: |
2.45(B) |
| Last
Volume: |
10,000 |
Avg
Vol: |
9,972 |
| 52
Week Range: |
$1.32 - $5.07 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 11.8 |
| Insider 6 Months : 12.4 |
| Insider 3/6 Months : 24.4 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Summit Therapeutics is holding company. Through its subsidiaries, Co. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicinal therapies. Co.'s primary product candidate, ridinilazole, is an oral small molecule antibiotic in clinical trial program, which evaluating ridinilazole for treating patients suffering from clostridioides difficile infection. Co.'s other product candidate, SMT026738 (SMT-738), is a small molecule inhibitor of bacterial lipoprotein transport system treating multidrug resistant infections, including Carbapenem-resistant Enterobacteriaceae infections. SMT-738 is an antibiotic that has entered preclinical development.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
210,321 |
235,721 |
3,211,911 |
527,659,818 |
| Total Buy Value |
$786,094 |
$840,698 |
$5,840,697 |
$548,454,392 |
| Total People Bought |
2 |
2 |
3 |
4 |
| Total Buy Transactions |
4 |
6 |
7 |
18 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-21 |
2023-10-20 |
2023-04-21 |
2022-04-21 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Duggan Robert W |
Chief Executive Officer |
• • • |
2021-05-12 |
4 |
B |
$5.24 |
$59,557,426 |
D/D |
11,365,921 |
67,662,454 |
3.23 |
18% |
|
| Zanganeh Maky |
Chief Operating Officer |
• • – |
2021-05-12 |
4 |
B |
$5.24 |
$2,038,763 |
I/I |
389,077 |
2,643,319 |
2.66 |
18% |
|
| Powell David Jonathan |
Chief Scientific Officer |
• – – |
2020-11-30 |
4 |
S |
$4.44 |
$60,886 |
D/D |
(13,713) |
0 |
|
-22% |
|
| Powell David Jonathan |
Chief Scientific Officer |
• – – |
2020-11-30 |
4 |
OE |
$1.79 |
$24,546 |
D/D |
13,713 |
13,713 |
|
- |
|
| Powell David Jonathan |
Chief Scientific Officer |
• – – |
2020-11-27 |
4 |
S |
$4.39 |
$129,808 |
D/D |
(29,569) |
0 |
|
-30% |
|
| Powell David Jonathan |
Chief Scientific Officer |
• – – |
2020-11-27 |
4 |
OE |
$1.79 |
$55,089 |
D/D |
29,569 |
29,569 |
|
- |
|
| Powell David Jonathan |
Chief Scientific Officer |
• – – |
2020-11-25 |
4 |
S |
$4.32 |
$52,142 |
D/D |
(12,070) |
0 |
|
-27% |
|
| Powell David Jonathan |
Chief Scientific Officer |
• – – |
2020-11-25 |
4 |
OE |
$1.92 |
$23,174 |
D/D |
12,070 |
12,070 |
|
- |
|
| Powell David Jonathan |
Chief Scientific Officer |
• – – |
2020-11-24 |
4 |
S |
$4.21 |
$47,885 |
D/D |
(11,374) |
0 |
|
-43% |
|
| Powell David Jonathan |
Chief Scientific Officer |
• – – |
2020-11-24 |
4 |
OE |
$1.92 |
$21,838 |
D/D |
11,374 |
11,374 |
|
- |
|
| Powell David Jonathan |
Chief Scientific Officer |
• – – |
2020-11-23 |
4 |
S |
$4.40 |
$30,743 |
D/D |
(6,987) |
0 |
|
-43% |
|
| Powell David Jonathan |
Chief Scientific Officer |
• – – |
2020-11-23 |
4 |
OE |
$1.92 |
$13,415 |
D/D |
6,987 |
6,987 |
|
- |
|
| Zanganeh Maky |
Director |
– • – |
2020-11-11 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,358,783 |
|
41% |
|
| Duggan Robert W |
Chief Executive Officer |
• • • |
2020-11-06 |
4 |
B |
$3.34 |
$46,999,999 |
D/D |
14,071,856 |
56,296,533 |
3.23 |
86% |
|
| Duggan Robert W |
See RemarksOfficer |
• • • |
2020-09-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
42,224,677 |
|
106% |
|
| Houbiers Jos |
Chief Medical OfficerOfficer |
• – – |
2020-09-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,512 |
|
106% |
|
| Stefanov Ventzislav |
See RemarksOfficer |
• • – |
2020-09-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
14,900 |
|
106% |
|
17 Records found
|
1
|
Page 1 of 1 |
|
|
0.01 (0.29%) 
